AbbVie (ABBV) has completed its acquisition of Capstan Therapeutics, bringing the biotech company under its umbrella.
Capstan's lead program, CPTX2309, is a Phase 1 tLNP-based therapy that generates CD19-specific, CD8+ in vivo CAR-T cells to target B cell-mediated autoimmune diseases. This approach aims for rapid and sustained B cell depletion without lymphodepleting chemotherapy, avoiding the limitations of traditional ex vivo CAR-T treatments.
AbbVie executives stated that the acquisition enhances its ability to reset the immune system through novel therapies and expands the application of Capstan's proprietary technology for in vivo cell programming.
ABBV currently trades at $205.54 or 0.50% lower on the NYSE.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.